 SAN CARLOS, Calif., March 08, 2022 GLOBE NEWSWIRE -- Iovance Biotherapeutics, Inc. NASDAQ: IOVA, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced the acceptance of two abstracts for presentation at the upcoming American Association for Cancer Research AACR 2022 Annual Meeting April 8-13, 2022 in New Orleans, Louisiana and virtual. Details for the abstracts are as follows: 